These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8866490)

  • 1. Cabergoline in Parkinson's disease complicated by motor fluctuations.
    Geminiani G; Fetoni V; Genitrini S; Giovannini P; Tamma F; Caraceni T
    Mov Disord; 1996 Sep; 11(5):495-500. PubMed ID: 8866490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease.
    Inzelberg R; Nisipeanu P; Rabey MJ; Korczyn AD
    Mov Disord; 1995 Sep; 10(5):604-7. PubMed ID: 8552112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
    Porter MC; Appiah-Kubf LS; Chaudhuri KR
    Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
    Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
    J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys.
    Bélanger N; Grégoire L; Hadj Tahar A; Bédard PJ
    Mov Disord; 2003 Dec; 18(12):1436-41. PubMed ID: 14673879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.
    Ahlskog JE; Muenter MD; Maraganore DM; Matsumoto JY; Lieberman A; Wright KF; Wheeler K
    Arch Neurol; 1994 Dec; 51(12):1236-41. PubMed ID: 7986180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S68-71. PubMed ID: 12211142
    [No Abstract]   [Full Text] [Related]  

  • 10. Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
    Ohno H; Nakajima M; Fujioka S; Iwamoto K; Kawamura M
    J Clin Neurosci; 2009 Jun; 16(6):790-2. PubMed ID: 19286385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease.
    Rabey JM; Nissipeanu P; Inzelberg R; Korczyn AD
    Clin Neuropharmacol; 1994 Jun; 17(3):286-93. PubMed ID: 9316674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists.
    Del Dotto P; Gambaccini G; Caneparo D; Berti C; Bernardini S; Bonuccelli U
    Neurol Sci; 2003 Oct; 24(3):170-1. PubMed ID: 14598071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
    J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
    Fariello RG
    Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
    Ahlskog JE; Wright KF; Muenter MD; Adler CH
    Clin Neuropharmacol; 1996 Jun; 19(3):202-12. PubMed ID: 8726539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
    Vallette S; Serri K; Serri O
    Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second generation of dopamine agonists: pros and cons.
    Rabey JM
    J Neural Transm Suppl; 1995; 45():213-24. PubMed ID: 8748628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.